A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of R935788 [R 788, fostamatinib] in Patients With Rheumatoid Arthritis Who Have Failed at Least One Biologic

Trial Profile

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of R935788 [R 788, fostamatinib] in Patients With Rheumatoid Arthritis Who Have Failed at Least One Biologic

Completed
Phase of Trial: Phase II

Latest Information Update: 03 May 2017

At a glance

  • Drugs Fostamatinib (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms TASKI-3
  • Sponsors Rigel Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Mar 2012 This trial is recruiting in France.
    • 01 Feb 2011 Results published in the Arthritis and Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top